Search
Guangshengtang has proudly announced the successful enrollment and dosing of the first subject in the Phase III clinical trial of its groundbreaking hepatitis B drug, Niricovir GST-HG141. Developed by its subsidiary, Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., this milestone was achieved on July 25, 2025, at Shulan (Hangzhou) Hospital. GST-HG141 stands out as a novel hepatitis B core protein nucleocapsid modulator, belonging to a new class of anti-hepatitis B drugs with a unique mechanism of action. Guangshengtang holds exclusive global intellectual property rights for GST-HG141, a testament to its innovative prowess in the field. Currently, there are no comparable products available in the global market, underscoring the potential significance of this clinical advancement.
-
C114 Communication Network -
Communication Home
